Systemic Therapy for Melanoma
Published: June 2022
$9.95
Print Copy Information:
- 8 pages
- Multifold
- 80# Aqueous Coating
- 4.25" x 7.25"
- Ships in 5 – 10 business days
What's Inside
Bulk and Institutional Ordering
About the Authors
Additional Information
- Key Points
- Treatment Recommendations
- Neoadjuvant Systemic Therapy Cutaneous Melanoma Eligible for Resection
- Adjuvant Systemic Therapy Resected (Stage II, III, IV) Cutaneous Melanoma
- Systemic Therapy Options Unresectable/Metastatic Cutaneous Melanoma
- Systemic Therapy Options Non-Cutaneous Melanoma (Stage II or greater)
- Tables
- Reasonable dose/schedule details for recommended regimens – Adjuvant Therapy
- Reasonable dose/schedule details for recommended regimens – Unresectable/Metastatic Disease
- 2022 recommendations for uveal melanoma
- For purchases under 100 in quantity, we suggest placing the order directly through the website.
- We offer group/institutional licenses for multi-user accounts (discount amount varies depending on the number of users).
- We are proud to offer special discounts to medical schools, training programs, students and more.
- We offer bulk purchase discounts based on number of copies and number of titles.
Contact Us for more details
Founded in 1964, the American Society of Clinical Oncology is the world's leading professional organization for physicians and oncology professionals caring for people with cancer.
Description
This pocket guide is derived from recommendations in the American Society of Clinical Oncology Guideline. This resource is a practice tool based on ASCO® practice guidelines and is not intended to substitute for the independent professional judgment of the treating physician. Practice guidelines do not account for individual variation among patients. This pocket guide does not purport to suggest any particular course of medical treatment. Use of the practice guidelines and this resource are voluntary. The practice guidelines and additional information are available at www.asco.org/melanoma-guidelines. Copyright © 2022 by American Society of Clinical Oncology. All rights reserved.
You can also find this product included in this bundle!
$
662.95
Print
Included Guidelines:
- Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer
- Adjuvant Therapy for Stage III Colon Cancer
- Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
- Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer – Brain Metastases
- Antiemetics
- Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression
- Appropriate Systemic Therapy Dosing for Obese Adult Patients with Cancer
- Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy
- Axilla Management in Early-Stage Breast Cancer
- Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer
- Biomarkers for Systemic Therapy in Metastatic Breast Cancer
- Bone-Modifying Agents in Metastatic Breast Cancer
- Bone-Modifying Agents in Multiple Myeloma
- Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents
- Cardiac Dysfunction - Prevention and Monitoring in Cancer Survivors
- Cervical Cancer Prevention
- Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma
- Chemotherapy-Naïve Castration-Resistant Prostate Cancer
- Chronic Pain in Survivors of Adult Cancers
- Clear Cell Renal Cell Carcinoma
- Colorectal Cancer Biomarkers
- Colorectal Cancer Early Detection
- Diagnosis and Management of Squamous Cell Carcinoma of Unknown Primary in the Head and Neck
- Diffuse Astrocytic and Oligodendroglial Tumors in Adults
- Early-Stage Breast Cancer
- Estrogen and Progesterone Receptor Testing in Breast Cancer
- Exercise, Diet, and Weight Management During Cancer Treatment
- Fertility Preservation
- Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer
- Hepatitis B Virus Screening and Management for Patients with Cancer Prior to Therapy
- HER2 Testing in Breast Cancer
- Hormone Receptor–Positive Breast Cancer Adjuvant Endocrine Therapy
- HR-Positive, HER2-Negative Metastatic Breast Cancer
- Immune-related Adverse Events from Immune Checkpoint Inhibitor Therapy
- Immune-related Adverse Events — CAR T-Cell Therapy
- Initial Management of Noncastrate Advance, Recurrent, or Metastatic Prostate Cancer
- Integrative Medicine for Pain Management in Oncology
- Invasive Cervical Cancer
- Laryngeal Cancer
- Late-Stage Colorectal Cancer
- Lung Cancer Surveillance After Definitive Curative-Intent Therapy
- Malignant Pleural Mesothelioma
- Management of Cancer Cachexia
- Management of Dyspnea in Advanced Cancer
- Management of Hereditary Breast Cancer
- Management of Male Breast Cancer
- Management of Osteoporosis
- Management of Salivary Gland Malignancy
- Management of the Neck in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx
- Medication-Related Osteonecrosis of the Jaw
- Metastatic HER2-Negative Breast Cancer – Chemo- and Targeted Therapy
- Metastatic Pancreatic Cancer
- Molecular Biomarkers in Localized Prostate Cancer
- Multiple Myeloma
- Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer
- Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer
- Non-Small Cell Lung Cancer — Adjuvant Therapy for Completely Resected Stages I-IIIA
- Optimum Imaging Strategies for Advanced Prostate Cancer
- Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy
- Ovarian Masses and Treatment of Epithelial Ovarian Cancer
- Palliative Care in the Global Setting
- Pancreatic Cancer - Evaluating Susceptibility
- PARP Inhibitors in the Management of Ovarian Cancer
- Platelet Transfusion
- Potentially Curable Pancreatic Adenocarcinoma
- Prevention And Management Of Chemotherapy-Induced Peripheral Neuropathy In Survivors Of Adult Cancers
- Salivary Gland Hypofunction and/or Xerostomia
- Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer
- Small Renal Masses
- Somatic Genomic Testing for Metastatic or Advanced Cancer
- Stage II Colon Cancer Adjuvant Therapy
- Stage III Non-Small Cell Lung Cancer
- Stage IV Non-Small Cell Lung Cancer without Driver Alterations
- Systemic Therapy for Advanced Hepatocellular Carcinoma
- Systemic Therapy for Melanoma
- Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations
- Treatment for Brain Metastases
- Treatment of Early-Stage Colorectal Cancer
- Treatment of Locally Advanced Esophageal Carcinoma
- Treatment of Metastatic Carcinoma and Myeloma of the Femur
- Use of Endocrine Therapy for Breast Cancer Risk Reduction
- Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer
- White Blood Cell Growth Factors
Related Guidelines
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer
Last Updated: Apr 13, 2022
Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer
Last Updated: Jan 17, 2022
